International Biotechnology Trust’s Sage Therapeutics SAGE Stock Holding History

International Biotechnology Trust’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,000	Closed	-$939K	–	68
2023 Q2	$939K	Buy	+20,000	New	+$995K	0.29%	48
2021 Q2	–	Sell	-21,500	Closed	-$1.61M	–	70
2021 Q1	$1.61M	Buy	+21,500	New	+$1.76M	0.43%	37
2020 Q3	–	Sell	-37,600	Closed	-$1.57M	–	55
2020 Q2	$1.57M	Hold	37,600	–	–	0.52%	31
2020 Q1	$1.08M	Sell	37,600 -3,800	-9%	-$220K	0.49%	33
2019 Q4	$2.98M	Buy	41,400 +25,400	+159%	+$3.12M	1.07%	27
2019 Q3	$2.25M	Sell	16,000 -17,996	-53%	-$3.01M	1.04%	23
2019 Q2	$6.22M	Hold	33,996	–	–	2.31%	16
2019 Q1	$5.41M	Buy	33,996 +18,000	+113%	+$2.61M	2%	20
2018 Q4	$1.2M	Hold	15,996	–	–	0.75%	31
2018 Q3	$1.73M	Sell	15,996 -27,000	-63%	-$4.17M	0.82%	33
2018 Q2	$6.73M	Sell	42,996 -27,500	-39%	-$4.32M	2.58%	16
2018 Q1	$11.3M	Buy	70,496 +19,000	+37%	+$3.23M	4.43%	7
2017 Q4	$8.48M	Buy	51,496 +34,500	+203%	+$3.34M	2.99%	11
2017 Q3	$1.06M	Hold	16,996	–	–	0.41%	45
2017 Q2	$1.35M	Hold	16,996	–	–	0.51%	44
2017 Q1	$1.21M	Hold	16,996	–	–	0.46%	44
2016 Q4	$867K	Buy	+16,996	New	+$801K	0.39%	39

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's SAGE Position: Q3 2023 in Review

International Biotechnology Trust sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 20,000 shares — an estimated $939K sold.

International Biotechnology Trust first reported a position in SAGE in Q4 2016 and held it in 17 quarters. The position peaked at $11.3M in Q1 2018. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

International Biotechnology Trust reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
International Biotechnology Trust sold 20,000 Sage Therapeutics shares in Q3 2023, an estimated $939K.
International Biotechnology Trust first reported a position in Sage Therapeutics in Q4 2016 and held it in 17 quarters.
International Biotechnology Trust's Sage Therapeutics position peaked at $11.3M in Q1 2018.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.